Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Venkatachalam, Senthil
- Personalized Nano Delivery Strategy in Treating Uveitis
Abstract Views :170 |
PDF Views:0
Authors
Arun Radhakrishnan
1,
Gowthamarajan Kuppusamy
1,
Senthil Venkatachalam
1,
Rohithkrishnan Vijayakumar
1,
Nikhitha K. Shanmukhan
1
Affiliations
1 Department of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam JSS Academy of Higher Education and Research, IN
1 Department of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam JSS Academy of Higher Education and Research, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 4 (2019), Pagination: 1997-2008Abstract
Uveitis is an inflammatory disease causes the damage of eye tissues and leads to the loss of vision once kept untreated. Early detection and identification of the disease are necessary for the prevention of the progressing inflammation and tissue damage. Existing treatment comprise of the administration of oral steroids, immunosuppressant, biological and adjuvant therapy. Even though topical, intravitreal and subconjunctival administration routes have been chosen for the drug administration, they fail to achieve the drug concentration to elicit a better therapeutic action due to the presence of ocular barriers such as tear, cornea conjunctiva, sclera, choroid membrane, retina, and blood-retinal barrier. Design of delivery systems that can prolong the precorneal habitation time increase the drug release as well as reduce the side effects such as methods to achieve prolonged can promise effective ocular drug delivery. Delivery systems such as hydrogels, liposomes, micro carrier systems, vitreous implants, medicated lenses, nanotechnology approaches such as nanocrystals, nanoemulsions, nanosuspensions, dendrimers, microneedles etc. exist as current research and the future research perspectives to achieve effective ocular drug delivery.Keywords
Uveitis, Classification, Treatment, Current Status of Therapy, Novel Ocular Drug Delivery.
References
- Zhu J, Zhang E, Rio‐Tsonis D. Eye Anatomy. eLS. 2012.
- Al-Dhibi H, Al-Mahmood A, Arevalo J. A. systematic approach to emergencies in uveitis. Middle East African J Ophthalmology, 2014; 21:251-258.
- Nussenblatt R. The natural history of uveitis. International Ophthalmology. 1990; 14:303-308.
- Mustafa M, Muthusamy P, Hussain S. Uveitis: Pathogenesis, Clinical presentations and Treatment. IOSR J Pharmacy (IOSRPHR). 2014; 04:42-47
- Van Laar J, Rothova A, Missotten T. Diagnosis and treatment of uveitis, not restricted to the ophthalmologist.J Clin Transl Res. 2015; 2:94-99
- Lowder C.Y, Char D.H. Uveitis-A review Medical Progress. West J Medicine. 1984; 140:421-432.
- Babu, M., Rathinam, S. Intermediate uveitis. Indian J Ophthalmology. 2010; 58:21-27
- Mustaf M, Muthusamy P, Hussain S.S.Uveitis: Pathogenesis, Clinical presentations and Treatment. IOSR J Pharm., 2014; 4:42-47.
- Biswas J, Sudharshan S, Ganesh S. Current approach in the diagnosis and management of posterior uveitis. Indian J Ophthalmol. 2010; 58:29-43
- Murtaza Mustafa P. MuthusamyS.S, Hussain S.C, Shimmi M.M. Sein. Uveitis: Pathogenesis, Clinical presentations and Treatment. IOSR J of Pharm. 2014; 4:42-47.
- Lin P, Suhler E.B, Rosenbaum J.T. The future of uveitis treatment. Ophthalmol. 2014; 121:365-76.
- Mérida S, Palacios E, Navea A, Bosch-Morell F. New immunosuppressive therapies in uveitis treatment. Int. J. Mol. Sci. 2015; 16:18778-95.
- Horai R, Caspi R.R. Cytokines in autoimmune uveitis. J Interferon Cytokine Res. 2011; 31:733–44.
- Multicenter Uveitis Steroid Treatment Trial Research Group. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010; 149:550-61.
- Ng D, Mohamed S, Chu W.K, Luk F.O, Brelén M, Chan C.K. Update on the management of non-infectious uveitis. Hong Kong Journal of Ophthalmology. 2016; 20:95-105.
- Van Laar J, van Velthoven M, Missotten T, Kuijpers R, van Hagen M, Rothová A. Diagnosis and treatment of uveitis, not restricted to the ophthalmologist. Ned. Tijdschr. Geneeskd. 2013; 157:5703
- Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G, Rakus Z, Gottschalk R, Stark S, Brodt H.R, Staszewski S. Comparing Quantiferon-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. Aids. 2008; 22:2471-9.
- Shakarchi F. Ocular tuberculosis: current perspectives. Clin Ophthalmol. 2015; 9:2223-7.
- Gupta V, Al-Dhibi H.A, Arevalo J.F. Retinal imaging in uveitis. Saudi J Ophthalmol 2014; 28:95-103.
- Leder H.A, Campbell J.P, Sepah Y.J, Gan T, Dunn J.P, Hatef E, Cho B, Ibrahim M, Bittencourt M, Channa R, Do DV. Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. Journal of ophthalmic inflammation and infection. 2013; 3:30.
- Babu K, Mahendradas P. Medical Management of Uveitis - Current Trends. Indian J Ophthalmology. 2013; 61:277-283
- John H.K, Altaweel M.M, Holbrook J.T, Multicenter Uveitis Steroid Treatment Trial Research Group. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.Am J Ophthalmol. 2010; 149:550-61.
- Jan A.M, Rothova A, Missotten T, Kuijpers R, van Hagen M, Rothova A. Diagnosis and treatment of uveitis, not restricted to the ophthalmologist. Nederlands tijdschrift voor geneeskunde., 2015; 2:94-99.
- Durrani, O.M., Tehrani, N.N., Marr, J.E., Moradi, P., Stavrou, P., Murray, P.I. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004, 88, 1159-62.
- Sudharshan S, Ganesh S.K, Balu G, Utility of QuantiFERON(R)-TB Gold test in diagnosis and management of suspected tubercular uveitis in India. Int Ophthalmol 2012; 32:217-223.
- Kempen J.H, Van Natta, M.L, Altaweel M.M., Dunn J.P, Jabs D.A, Lightman, S.L, et al. Factors predicting visual acuity outcome in intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment (MUST) trial. Am. J. Ophthalmol. 2015; 160:1133-41.
- Bansal R, Gupta V, Gupta A. Current approach in the diagnosis and management of panuveitis. Indian J Ophthalmol. 2010; 58:45-54.
- Pasadhika S, Suhler E.B, Cunningham, E.T. Biologic therapy for posterior uveitis and panuveitis. Retina today. 2012; 4:74-9.
- Nussenblatt R.B, Peterson J.S, Foster C.S, Rao N.A, See R.F, Letko E, Buggage R.R. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmol., 2005; 112:764-70.
- Mutlukan E. Investigation and management of uveitis. BMJ. 2010; 341.
- Goldhardt R, Rosen B.S. Uveitic macular edema: treatment update. Curr Ophthalmol Rep. 2016; 4:30–37.
- Park Y, Nam H. Clinical features and treatment of ocular toxoplasmosis. Korean J Parasitol. 2013; 51:393-399.
- Gaudana R, Ananthula H.K, Parenky A, Mitra A.K. Ocular drug delivery. The AAPS journal. 2010; 12:348-60.
- Patel A, Cholkar K, Agrahari V, Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World journal of pharmacology. 2013; 47–64.
- Cholkar K, Patel S.P, Vadlapudi A.D, Mitra A.K. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013; 29:106-23.
- He Y, Jia, S.B, Zhang W, Shi J.M. New options for uveitis treatment. International journal of ophthalmology. 2013; 6:702.
- Lin P, Suhler E.B, Rosenbaum J.T. The future of uvetis treatment. Ophthalmology Trans Sci Rev. 2014; 121:365-376.
- Gupta S, Rajesh K.S. Ophthalmic drug delivery systems with emphasis on in-situ hydrogels. Pharmagene, 2013; 1:80-87.
- Ansel H.C, Allen, L.V, Popovich N.G. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 9th ed.Baltimore(MD). Lippincott Williams and Wilkins, 2011.
- Singh K, Harikumar S.L. Injectable in-situ gelling controlled release drug delivery system. Int. j. drug dev. res. 2012; 4:56-69.
- Davies N.M. Biopharmaceutical considerations in topical ocular drug delivery. Clin and exp pharmacol and physiol. 2000; 27:558-562.
- Kuno N, Fujii S. Recent Advances in Ocular Drug Delivery Systems. Polymers. 2011; 3:193-221.
- Dhanapal R, Ratna V.J. Ocular drug delivery system – a review. Int J Innovative Drug Discovery. 2012; 2:4-15.
- Jaffe G, Ben-nun J, Guo H, Dunn J.P, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmol, 2000; 107:2024-33.
- Nussenblatt R, Peterson J, Foster C, Rao N.A, See R.F, Letko E, Buggage R.R. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmol, 2005; 112:764-770.
- Yuan He, Jian-Cheng Wang, Yu-LingLiu, Zhi-Zhong Ma, Xiu-An Zhu, Qiang Zhang. Therapeutic and Toxicological Evaluations of Cyclosporine A Microspheres as a Treatment Vehicle for Uveitis in Rabbits. J Ocul Pharmacol Ther 2006; 22:121-131.
- Higuchi J. W, Higuchi W.I, Li S.K, et al. Noninvasive Delivery of a Transscleral Sustained Release Depot of Triamcinolone Acetonide Using the Visulex Device to Treat Posterior Uveitis. J iovs. 2007, 48, 5822.
- Adibkia K, Omidi Y, Siahi M.R, Javadzadeh A.R., Barzegar-Jalali, M., Barar, J., Maleki, N., Mohammadi G, Nokhodchi, A. Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J Ocul Pharmacol Ther, 2007; 23:421-32.
- Barcia E, Herrero-Vanrell R., Diez A., Alvarez-Santiago C, Lopez 1, Calonge, M, Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp Eye Res. 2009; 89: 238—245.
- Lajavardi L, Camelo S, Agnely F, et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J Controlled Release 2009; 139:22-30.
- Shen J, Gan L, Zhu C, et al. Novel NSAIDs ophthalmic formulation: Flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect. International Journal of Pharmaceutics. 2011; 412:115-122.
- Kilmartin D, Forrester J, Dick A, Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br. J. Ophthalmol. 1998; 82:737-742.
- Harikumar S.L, Sonia A. Nanotechnological approaches in Ophthalmic delivery systems. Int J Drug Dev & Res. 2011; 3:9-19.
- Webb, P.A, Orr, C. Analytical Methods in Fine Particle Technology, Micromeritics Instrument Corp. Norcros. Stud in Surf Sci and Catal1997; 273–280.
- Amrite A.C, Kompella U.B. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005; 57:1555-1563.
- Sukari E and Flora D. The effect of Particle Size of Polymeric Nanospheres on Intraviteral Kinetics. Opthalomol Resear. 2001; 33:31-36.
- Donnelly R.F, Raj Singh T.R, Woolfson A.D. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv 2010; 17:187–207.
- Lee S.S, Hughes P, Ross A.D, Robinson M.R. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010; 27:2043–2053.
- Patton T.F, Robinson J.R. Ocular Evaluation of Polyvinyl alchol vechile in rabbits. J. A. pharm.Sci.1975; 64:1312-1316.
- Hathout R.M, Mansour S, Mortada N.D, Guinedi A.S. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech. 2007; 5:1.
- Mandal A, Bisht R, Rupenthal I.D, Mitra A.K. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.J. Control. Release. 2017; 248:96-116.
- Milhe O.M, Myles C, Yamakawa J, McKeown N.B, Attwood D, D’Emanuele A. Polyamidoamine Starburst® dendrimers as solubility enhancers. International journal of pharmaceutics. 2000; 197:239-41.
- Rajoria G, Gupta A. In-situ gelling system: a novel approach for ocular drug delivery. Am J Pharm Tech Res 2012; 2:24-53.
- Indu P.K, Manjit S, Meenakshi K. Formulation and Evaluation of Ophthalmic Preparations of Acetazolamide.Int J Pharm 2000; 199:119-127.
- Repurposing Drugs for Management of Alzheimer Disease
Abstract Views :192 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Tamilnadu-643001, IN
2 Affiliated by JSS Academy of Higher Education and Research, Mysuru, Karnataka, IN
1 Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Tamilnadu-643001, IN
2 Affiliated by JSS Academy of Higher Education and Research, Mysuru, Karnataka, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 6 (2019), Pagination: 3078-3088Abstract
Alzheimer's disease (AD), or Alzheimer’s, It is neurodegenerative disease starts very slowly and with time it got worse one of the biggest challenge of the CNS drug delivery scientist. Mental and physic exercise, Cholinesterase Inhibitors, and avoiding adipositas may reduce the risk of the AD. Currently, existing/approved drugs for the treatment of the AD are based on neurotransmitter or enzyme replacement/modulation. Existing therapies gives just an optimum advantage and consequently, in present, there is an evident desire for advanced medications or therapies. Drug repurposing is one of the latest trend and the alternative approach in drug advancement, with a history of successful reuse of currently available drugs. A signify category of the drugs reuse in the management of the AD among them the prominent category is the anticancer, antiepileptic, antibiotics, ant diabetic etc. The review focuses on mechanism and application for the repurposing of the existing drugs in the light of the clinical and pre-clinical evidences.Keywords
Alzheimer’s Disease, Repurposing Drugs, Repurposed Drugs Pathways, Preclinical Data, Clinical Evidences.References
- Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Science translational medicine.2011, 3(77), sr1-sr1.
- Reisberg B, Ferris S, De Leon M. Senile dementia of the Alzheimer type: Diagnostic and differential diagnostic features with special reference to functional assessment staging. Senile dementia of the Alzheimer type: Springer; 1985, 18-37.
- Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992, 256(5054),184.
- Duyc kaerts C, Potier M-C, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta neuropathologica. 2008, 115(1), , 5-38.
- Larson EB, Shadlen M-F, Wang L, McCormick WC, Bowen JD, Teri L, et al. Survival after initial diagnosis of Alzheimer disease. Annals of internal medicine. 2004, 140(7), 501-9.
- Association As. 2017 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2017, 13(4), 325-73.
- Fox PJ. Alzheimer's Disease: An Historical Overview. American Journal of Alzheimer's Care and Related Disorders. 1986, 1(4), 18-24.
- Cipriani G, Danti S, Carlesi C. Three men in a (same) boat: Alzheimer, Pick, Lewy. Historical notes. European Geriatric Medicine. 2016, 7(6), 526-30.
- Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nature Reviews Neuroscience. 2008, 9(10), 768.
- Whitehouse PJ, George D. The myth of Alzheimer's: What you aren't being told about today's most dreaded diagnosis: Macmillan; 2008.
- Janus C. Vaccines for Alzheimer’s disease. CNS drugs. 2003, 17(7), 457-74.
- Finger EA. Alzheimer Demenz. 2015.
- Helmuth L. New Alzheimer's treatments that may ease the mind. American Association for the Advancement of Science; 2002.
- Hutton M, Pérez-Tur J, Hardy J. Genetics of Alzheimer’s. Essays in biochemistry. 1998, 33.
- Selkoe DJ. Amyloid β-protein and the genetics of Alzheimer's disease. Journal of Biological Chemistry. 1996, 271(31), 18295-8.
- St George-Hyslop PH. Molecular genetics of Alzheimer’s disease. Biological psychiatry. 2000, 47(3), 183-99.
- Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. science. 1999, 286(5440), 735-41.
- Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature medicine. 1996, 2(8), 864.
- Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. The international journal of biochemistry & cell biology. 2007, 39(1),44-84.
- Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chemical research in toxicology. 2007, 21(1), 172-88.
- Ittner LM, Götz J. Amyloid-β and tau—a toxic pas de deux in Alzheimer's disease. Nature Reviews Neuroscience. 2011, 12(2), 67.
- Mandelkow E-M, Mandelkow E. Tau in Alzheimer's disease. Trends in cell biology. 1998, 8(11), 425-7.
- Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. Journal of Neurology, Neurosurgery & Psychiatry. 1999, 66(2), 137-47.
- Bartus RT, Dean Rr, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982, 217(4558), 408-14.
- Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. The American Journal of Geriatric Psychiatry. 1998, 6(2), S64-S78.
- Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Bmj. 2005, 331(7512),321-7.
- Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clinical interventions in aging. 2008, 3(2),211.
- Jacob C, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. Journal of Alzheimer's Disease. 2007, 11(1), 97-116.
- Uddin MS, Al Mamun A, Kabir MT, Jakaria M, Mathew B, Barreto GE, et al. Nootropic and Anti-Alzheimer’s Actions of Medicinal Plants: Molecular Insight into Therapeutic Potential to Alleviate Alzheimer’s Neuropathology. Molecular neurobiology. 2018,1-20.
- Giacobini E. Invited Review Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications. Neurochemistry international. 1998, 32(5-6), 413-9.
- Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer’s disease. Drugs. 2001, 61(1), 1-52.
- Jones R. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life and allied sciences. 2010, 25(6), 547-53.
- Kumar A, Singh A. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacological Reports. 2015, 67(2), 195-203.
- Witt A, Macdonald N, Kirkpatrick P. Memantine hydrochloride. Nature Publishing Group; 2004.
- De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, et al. Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. Journal of Biological Chemistry. 2007, 282(15), 11590-601.
- Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proceedings of the National Academy of Sciences. 1997, 94(6), 2642-7.
- Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS medicine. 2009, 6(9), e1000157.
- Pardridge WM. Blood–brain barrier delivery. Drug discovery today. 2007, 12(1-2), 54-61.
- Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nature reviews Drug discovery. 2004, 3(8), 673.
- Boolell M, Gepi‐Attee S, Gingell J, Allen M. Sildenafil, a novel effective oral therapy for male erectile dysfunction. British journal of urology. 1996, 78(2),257-61.
- Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dementia and geriatric cognitive disorders. 2013, 35(1-2), 1-22.
- Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, et al. Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proceedings of the National Academy of Sciences. 2010, 107(41), 17763-7.
- Monacelli F, Cea M, Borghi R, Odetti P, Nencioni A. Do cancer drugs counteract neurodegeneration? Repurposing for alzheimer’s disease. Journal of Alzheimer's Disease. 2017, 55(4),1295-306.
- Roe CM, Behrens M, Xiong C, Miller J, Morris J. Alzheimer disease and cancer. Neurology. 2005, 64(5), 895-8.
- Li G, Faibushevich A, Turunen BJ, Yoon SO, Georg G, Michaelis ML, et al. Stabilization of the cyclin‐dependent kinase 5 activator, p35, by paclitaxel decreases β-amyloid toxicity in cortical neurons. Journal of neurochemistry.2003, 84(2), 347-62.
- Michaelis M, Ranciat N, Chen Y, Bechtel M, Ragan R, Hepperle M, et al. Protection against β‐amyloid toxicity in primary neurons by paclitaxel (taxol). Journal of neurochemistry. 1998, 70(4), 1623-7.
- O'hare E, Jeggo R, Kim E-M, Barbour B, Walczak J-S, Palmer P, et al. Lack of support for bexarotene as a treatment for Alzheimer's disease. Neuropharmacology. 2016, 100, 124-30.
- Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J. Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiology of aging. 2014, 35(9), 2091-5.
- Cramer PE, Cirrito JR, Wesson DW, Lee CD, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. science. 2012, 335(6075), 1503-6.
- Bachmeier C, Beaulieu-Abdelahad D, Crawford F, Mullan M, Paris D. Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood–brain barrier. Journal of Molecular Neuroscience. 2013, 49(2), 270-6.
- Frischer H, Ahmad T. Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU [1, 3-bis (chloroethyl)-1-nitrosourea]. The Journal of laboratory and clinical medicine. 1977, 89(5), 1080-91.
- Hayes CD, Dey D, Palavicini JP, Wang H, Patkar KA, Minond D, et al. Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine. BMC medicine. 2013, 11(1), 81.
- Araki W. Potential repurposing of oncology drugs for the treatment of Alzheimer's disease. BMC medicine. 2013, 11(1), 82.
- Jin N. Opposite effects of lithium and valproic acid on trophic deprivation-induced GSK-3 (Beta) activation, c-Jun expression and neuronal cell death. 2004.
- Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, et al. Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. Journal of Experimental Medicine. 2008, 205(12), 2781-9.
- Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. The Journal of clinical investigation.2012, 123(1).
- Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. Journal of neurochemistry. 2008, 104(6), 1433-9.
- Leng Y, Chuang D-M. Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. Journal of Neuroscience. 2006, 26(28), 7502-12.
- Yao Z-G, Jing H-Y, Wang D-M, Lv B-B, Li J-M, Liu F-F, et al. Valproic acid ameliorates olfactory dysfunction in APP/PS1 transgenic mice of Alzheimer's disease: ameliorations from the olfactory epithelium to the olfactory bulb. Pharmacology Biochemistry and Behavior. 2016, 144, 53-9.
- Kim H-S, Suh Y-H. Minocycline and neurodegenerative diseases. Behavioural brain research. 2009, 196(2), 168-79.
- Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Progress in Neuropsychopharmacology & Biological Psychiatry. 2008, 7(32),1758-9.
- Mao J. Glutamate transporter: an unexpected target for some antibiotics. Molecular pain. 2005, 1(1), 5.
- Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005, 433(7021),73.
- Tomiyama T, Shoji A, Kataoka K-i, Suwa Y, Asano S, Kaneko H, et al. Inhibition of amyloid protein aggregation and neurotoxicity by rifampicin its possible function as a hydroxyl radical scavenger. Journal of Biological Chemistry. 1996, 271(12), 6839-44.
- Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. Journal of the American Geriatrics Society. 2004, 52(3), 52(3), 381-7.
- He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease. Nature. 2010, 467(7311), 95.
- Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular engineering. 2001, 17(6), 157-65.
- Balducci C, Mehdawy B, Mare L, Giuliani A, Lorenzini L, Sivilia S, et al. The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. Journal of Alzheimer's Disease. 2011, 24(4), 799-816.
- Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. Journal of Alzheimer's Disease. 2012, 31(1), 151-65.
- Yulug B, Hanoglu L, Kilic E, Schabitz WR. RIFAMPICIN: an antibiotic with brain protective function. Brain research bulletin. 2014, 107, 37-42.
- Umeda T, Ono K, Sakai A, Yamashita M, Mizuguchi M, Klein WL, et al. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers. Brain. 2016, 139(5),1568-86.
- Abuznait AH, Cain C, Ingram D, Burk D, Kaddoumi A. Up‐regulation of P‐glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P‐glycoprotein as a novel therapeutic target for Alzheimer's disease. Journal of Pharmacy and Pharmacology. 2011, 63(8), 1111-8.
- Jenagaratnam L, McShane R. Clioquinol for the treatment of Alzheimer's Disease. Cochrane Database of Systematic Reviews. 2006.
- Froestl W, Pfeifer A, Muhs A. Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014. Journal of Alzheimer's Disease. 2014, 42(4), 1079-149.
- Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British journal of clinical pharmacology. 2012, 73(4), 504-17.
- Csiszar A, Tucsek Z, Toth P, Sosnowska D, Gautam T, Koller A, et al. Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in β-amyloid generation and Alzheimer's disease. American Journal of Physiology-Heart and Circulatory Physiology. 2013, 305(8), H1120-H30.
- Paris D, Bachmeier C, Patel N, Quadros A, Volmar C-H, Laporte V, et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Molecular Medicine.2011, 17(3-4), 149.
- Cho H, Ueda M, Shima K, Mizuno A, Hayashimatsu M, Ohnaka Y, et al. Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and anti-hypertensive activity. Journal of medicinal chemistry. 1989, 32(10), 2399-406.
- HOWLETT DR, GEORGE AR, MARKWELL RE. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer β-amyloid fibril formation. Biochemical Journal. 1999, 343(2), 419-23.
- Wang J, Ono K, Dickstein DL, Arrieta-Cruz I, Zhao W, Qian X, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiology of aging. 2011, 32(12), 2321. e1-. e12.
- Arrieta-Cruz I, Wang J, Pavlides C, Pasinetti GM. Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer's disease. Journal of Alzheimer's Disease. 2010, 21(2), 649-54.
- Daulatzai MA. Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer’s disease. Neurochemical research. 2012, 37(12), 2627-58.
- Wolk DA, Dickerson BC, Initiative AsDN. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer's disease. Proceedings of the National Academy of Sciences. 2010:201001412.
- Dhikav V, Anand K. Potential predictors of hippocampal atrophy in Alzheimer’s disease. Drugs & aging. 2011, 28(1), 1-11.
- Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. The American journal of geriatric psychiatry. 2005, 13(11), 950-8.
- Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Experimental neurology. 2006, 199(2), 265-73.
- Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. Journal of Neuroscience. 2012, 32(30), 10117-28.
- Escribano L, Simón A-M, Gimeno E, Cuadrado-Tejedor M, De Maturana RL, García-Osta A, et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology. 2010, 35(7), 1593.
- Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, et al. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice. Brain. 2005, 128(6), 1442-53.
- Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL, et al. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. Journal of Alzheimer's Disease. 2012, 30(4), 943-61.
- Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. Journal of Neuroscience. 2012, 32(48), 17321-31.
- Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998, 50(1), 164-8.
- Gasparini L, Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends in neurosciences. 2003, 26(8), 404-6.
- Steen E, Terry BM, J Rivera E, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease–is this type 3 diabetes? Journal of Alzheimer's disease. 2005, 7(1), 63-80.
- De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proceedings of the National Academy of Sciences. 2009:pnas. 0809158106.
- Qu T, Manev R, Manev H. 5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease. The Journal of neuropsychiatry and clinical neurosciences. 2001, 13(2), 304-5.
- Drazen JM, Yandava CN, Dubé L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature genetics. 1999, 22(2), 168.
- Paris D, Town T, Mori T, Parker TA, Humphrey J, Mullan M. Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiology of aging. 2000, 21(2), 183-97.
- Manev H, Uz T, Sugaya K, Qu T. Putative role of neuronal 5-lipoxygenase in an aging brain. The FASEB Journal. 2000, 14(10), 1464-9.
- Chu J, Li J-G, Pratico D. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer’s disease with plaques and tangles. PLoS One. 2013, 8(8), e70991.
- Costa Silva B, Silva de Miranda A, Guimaraes Rodrigues F, Leticia Malheiros Silveira A, Henrique de Souza Resende G, Flavio Dutra Moraes M, et al. The 5-lipoxygenase (5-LOX) inhibitor zileuton reduces inflammation and infarct size with improvement in neurological outcome following cerebral ischemia. Current neurovascular research. 2015, 12(4), 398-403.
- Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE. Phosphodiesterase 5 inhibitors for erectile dysfunction. Annals of Pharmacotherapy. 2005, 39(7-8),1286-95.
- Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. International journal of andrology. 2005, 28(5), 260-6.
- Cuadrado‐Tejedor M, Hervias I, Ricobaraza A, Puerta E, Pérez‐Roldán J, García‐Barroso C, et al. Sildenafil restores cognitive function without affecting β‐amyloid burden in a mouse model of Alzheimer's disease. British journal of pharmacology. 2011, 164(8), 2029-41.
- Garcia-Osta A, Aguirre N, Franco R, Garcia-Barroso C, Perez-Roldan J, Puerta E, et al. Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease. 2011.
- Ding Y, Qiao A, Wang Z, Goodwin JS, Lee E-S, Block ML, et al. Retinoic acid attenuates β-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. Journal of Neuroscience. 2008, 28(45), 11622-34.
- Jarvis C, Goncalves M, Clarke E, Dogruel M, Kalindjian S, Thomas S, et al. Retinoic acid receptor‐α signalling antagonizes both intracellular and extracellular amyloid‐β production and prevents neuronal cell death caused by amyloid‐β. European Journal of Neuroscience. 2010, 32(8),1246-55.
- Shudo K, Fukasawa H, Nakagomi M, Yamagata N. Towards retinoid therapy for Alzheimer's disease. Current Alzheimer Research. 2009, 6(3), 302-11.
- Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. Up-regulation of the α-secretase ADAM10 by retinoic acid receptors and acitretin. The FASEB Journal. 2009, 23(6), 1643-54.
- Radha Mahendran, Suganya Jeyabasker, Astral Francis, Sharanya Manoharan. Homology Modeling and in silico docking analysis of BDNF in the treatment of Alzheimer’s disease. Research J. Pharm. and Tech. 2017; 10(9): 2899-2906.
- Vivek Kumar Sharma. Current Therapeutic Strategies for Alzheimer’s disease: A Lost Direction or A Hope Remains?. Research J. Pharmacology and Pharmacodynamics. 2010; 2(3): 215-220.
- D Rajesh Kumar,M Siva Shankar,P Prathap Reddy, B Ram Sarath Kumar, N Sumalatha A Review on Alzheimer’s Disease. Research Journal of Pharmacology and Pharmacodynamics. 2014; 6(1): 59-63.
- M. Vijey Aanandhi, Niventhi. A, Rujaswini. T, Hemalatha C.N, Praveen. D. A Comprehensive Review on the Role of Tau Proteins in Alzheimer’s Pathology. Research J. Pharm. and Tech 2018; 11(2):788-790.
- Chirag K Patel, B Panigrahi, R Badmanaban, CN Patel. Biochemical Origins of Alzheimer’s Disease with Treatment Techniques. Research J. Pharmacology and Pharmacodynamics. 2010; 2(1):33-38.
- Saudagar RB, Buchake VV, Bachhav RS. Role of Retinoids in treatment of Alzheimer’s disease. Research J. Pharmacology and Pharmacodynamics. 2012; 4(3): 144-149 .
- Neveda Baskeran. Iron Deficiency and Brain Disorders. Research J. Pharm. and Tech. 7(3): Mar., 2014; Page 352-353.
- Sree Lekshmi. R. S, P. Shanmugasundaram. Neuroprotective Properties of Statins. Research J. Pharm. and Tech 2018; 11(8): 3581-3584.
- M. Vijey Aanandhi, Yeshwanth Prasanna Kumar. B, Ranadheer Chowdary. P, Praveen. D. A Review on the Role of Presenilin in Alzheimer’s Disease . Research J. Pharm. and Tech 2018; 11(5):2149-2151.
- Vasudev Pai, Chandrashekar K. S, C. S. Shreedhara, Aravinda Pai. In-Silico and In-Vitro correlation studies of natural β-secretase inhibitor: An approach towards Alzheimer’s Disease. Research J. Pharm. and Tech 2017; 10(10):3506-3510.